Endologix takes AAA (abdominal aortic aneurysms) graft to China:
This article was originally published in Clinica
China has given Endologix the all clear to market its PowerLink stent graft for the minimally invasive treatment of abdominal aortic aneurysms (AAA). The firm has begun shipping the product to physician training centres through its local distributor, Advanced Medical China. "We see a significant opportunity in China with that country's emerging middle class," said Paul McCormick, Endologix' president and CEO. In addition, the Irvine, California firm believes it will be the first to introduce a minimally invasive AAA treatment in Japan, where data from a completed trial of the product have already been filed.
You may also be interested in...
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.
In a final guidance from the US agency, regulators say most combination product questions are best resolved through traditional pathways and noted that initiating a so-called combination product agreement meeting may be unproductive.